Reviewing Cytokinetics Incorporated (CYTK)’s and Abeona Therapeutics Inc. (NASDAQ:ABEO)’s results

Cytokinetics Incorporated (NASDAQ:CYTK) and Abeona Therapeutics Inc. (NASDAQ:ABEO), both competing one another are Biotechnology companies. We will contrast their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cytokinetics Incorporated 10 19.83 N/A -1.93 0.00
Abeona Therapeutics Inc. 5 66.85 N/A -1.36 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Cytokinetics Incorporated and Abeona Therapeutics Inc.

Profitability

Table 2 has Cytokinetics Incorporated and Abeona Therapeutics Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Cytokinetics Incorporated 0.00% -269.2% -47.5%
Abeona Therapeutics Inc. 0.00% 0% 0%

Risk and Volatility

Cytokinetics Incorporated is 65.00% more volatile than S&P 500 due to its 1.65 beta. In other hand, Abeona Therapeutics Inc. has beta of 1.84 which is 84.00% more volatile than S&P 500.

Liquidity

The Current Ratio and Quick Ratio of Cytokinetics Incorporated are 7.1 and 7.1 respectively. Its competitor Abeona Therapeutics Inc.’s Current Ratio is 3.3 and its Quick Ratio is 3.3. Cytokinetics Incorporated can pay off short and long-term obligations better than Abeona Therapeutics Inc.

Analyst Recommendations

Cytokinetics Incorporated and Abeona Therapeutics Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cytokinetics Incorporated 0 0 3 3.00
Abeona Therapeutics Inc. 0 1 3 2.75

Cytokinetics Incorporated’s consensus price target is $18, while its potential upside is 45.28%. Abeona Therapeutics Inc. on the other hand boasts of a $17.17 consensus price target and a 478.11% potential upside. Based on the analysts opinion we can conclude, Abeona Therapeutics Inc. is looking more favorable than Cytokinetics Incorporated.

Institutional and Insider Ownership

Cytokinetics Incorporated and Abeona Therapeutics Inc. has shares held by institutional investors as follows: 70.9% and 64.4%. 1% are Cytokinetics Incorporated’s share held by insiders. Comparatively, insiders own roughly 0.3% of Abeona Therapeutics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cytokinetics Incorporated 4.28% 8.45% 46.51% 75.4% 63.62% 92.88%
Abeona Therapeutics Inc. -30% -45.7% -66.45% -60.7% -81.09% -63.73%

For the past year Cytokinetics Incorporated had bullish trend while Abeona Therapeutics Inc. had bearish trend.

Summary

On 5 of the 9 factors Abeona Therapeutics Inc. beats Cytokinetics Incorporated.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. The company is preparing for the commercialization of Tirasemtiv in North America and Europe, as well as has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. The company has strategic alliances with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator that is in two ongoing Phase II clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease, as well as other indications associated with muscle weakness; and with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, which is in Phase III clinical trial in patients with heart failure. Amgen Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and other countries; and Astellas Pharma Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil and related compounds. The company was founded in 1997 and is headquartered in South San Francisco, California.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The companyÂ’s lead programs are ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV-based gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, the company is developing plasma-based protein therapy pipeline, including SDF Alpha, an alpha-1 protease inhibitor for inherited COPD using its proprietary salt diafiltration ethanol-free process. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.